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Inclusion into PLGA nanoparticles greatly improves the effectiveness of α-bisabolol to inhibit 
human Dendritic Cell pro-inflammatory activity. 
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
α-bisabolol (Fig. 1) is a natural monocyclic 
sesquiterpene alcohol that has generated considerable 
interest for its biological effects, including its anti-
inflammatory activity [1]. Since the mechanisms 
leading to this anti-inflammatory action remain 
poorly understood, we investigated whether α-
bisabolol affects the release of pro-inflammatory 
cytokines by human dendritic cells (DCs). 
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Figure 1 Structure of -Bisabolol 
RESULTS AND DISCUSSION 
We found that α-bisabolol did not induce cytokine 
secretion and did not affect lipopolysaccharide 
(LPS)-induced cytokine release by DCs (Fig. 2). 
 
Figure 2: Cytokine secretion. 
 
 
 
 
As α-bisabolol is not easily ingested by cells, this 
lack of effects could be ascribed to its inability to 
reach intracellular targets. We then prepared PLGA 
nanoparticles (NPs) [2, 3], that were unable to affect 
per se cytokine secretion [4] by both resting and 
LPS-stimulated DCs (Fig. 2), and we loaded them 
with α-bisabolol. The inclusion of α-bisabolol into 
PLGA NPS did not stimulate cytokine secretion by 
resting DCs, but greatly depressed LPS-induced IL-
12, IL-6, and TNFα secretion (Fig. 2). A confocal 
microscopy analysis showed that α-bisabolol-loaded 
PLGA NPs are internalized by human DCs (Fig. 3). 
Our results indicate that α-bisabolol can inhibit 
inflammation by decreasing the secretion of pro-
inflammatory cytokines by DCs and suggest that the 
insertion of this compound into PLGA NPs 
represents a good way to promote its ingestion by the 
cells that can trigger its anti-inflammatory, anti-
pyretic and, possibly, immunosuppressive activity 
[5].  
 
 
 
 
 
 
 
 
 
Figure 3: Cellular uptake: 
In green the cellular membrane, 
in blue the nucleus and PLGA-
NPs in red 
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